Trial Profile
Phase 1 proof-of-concept clinical trial of KP-415 for the treatment of attention deficit hyperactivity disorder.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Mar 2023
Price :
$35
*
At a glance
- Drugs Serdexmethylphenidate (Primary) ; Methylphenidate
- Indications Attention-deficit hyperactivity disorder
- Focus Adverse reactions; First in man; Pharmacokinetics; Proof of concept
- 22 Feb 2023 According to a KemPharm media release, KemPharm has changed its name to Zevra Therapeutics.
- 18 Jan 2019 According to a KemParma media release, data from this study were presented at the 2019 Annual Meeting of the American Professional Society for ADHD and Related Disorders (APSARD).
- 28 Jun 2017 KemPharm held an EOP1 meeting with the FDA to discuss the data from this trial, as reported in a media release.